{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.38","upperLimit":"1.64","value":"1.45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Time to response was defined as the time from first dose to first radiographic evidence of response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Encorafenib + binimetinib + cetuximab. Encorafenib: Orally, once daily. Binimetinib: Orally, twice daily. Cetuximab: Standard of care.","id":"OG000","title":"Combined Safety Lead-in"}],"paramType":"MEDIAN","populationDescription":"The SLI Efficacy Set consisted of all CSLI participants in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).","reportingStatus":"POSTED","timeFrame":"From first dose to first radiographic evidence of response (maximum treatment exposure of 280 weeks)","title":"(Safety Lead-in) Time to Response by Investigator","type":"SECONDARY","unitOfMeasure":"Months"}